Key result
Combination antiplatelet therapies are evaluated for the treatment and prevention of atherothrombosis, with a critical balance required between anti-ischemic efficacy and bleeding risk.
Why the study?
Do combination antiplatelet therapies prevent atherothrombotic complications in patients with cardiovascular diseases?
Population
Patients with cardiovascular diseases and atherothrombosis
Design
Review
Authors
Loading...
Atherothrombosis burden in CVD warrants comprehensive antithrombotic consideration; leaves open optimal long-term regimens targeting systemic arterial disease.
Do combination antiplatelet therapies prevent atherothrombotic complications in patients with cardiovascular diseases?
This review highlights the critical balance between anti-ischemic efficacy and bleeding risk when using combination antiplatelet therapies for the treatment and prevention of atherothrombosis.
Gurbel et al. (2010) conducted a review in Atherothrombosis and cardiovascular diseases. Combination antiplatelet therapies was evaluated. Combination antiplatelet therapies are evaluated for the treatment and prevention of atherothrombosis, with a critical balance required between anti-ischemic efficacy and bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: